Otros idiomas EirGenix Inc.

Acciones

6589

TW0006589005

Precio de cierre Taipei Exchange Otros sitios de cotización 00:00:00 20/05/2024			Varia. Cinco días.	Varia. 1 de enero.
82,5 ^TWD	-0,72 %		+2,87 %	-17,91 %

22/03	EirGenix Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI
08/03	EirGenix, Inc. Resuelve firmar el contrato con la CRO clínica y las empresas pertinentes para el ensayo clínico de fase III del EG1206A	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	08/03
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC	23/11
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei	09/11
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar	18/09/23
Novartis : avis favorable pour un biosimilaire du trastuzumab	18/09/23
Novartis-Krebsmedikament Trastuzumab erhält EMA-Empfehlung	18/09/23
Sandoz décroche un avis positif du CHMP pour le trastuzumab	18/09/23
Novartis Cancer Drug Gets Marketing Recommendation from European Medicines Agency	18/09/23
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar	18/09/23
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System	18/09/23
Sandoz erhält positive CHMP-Stellungnahme für Krebs-Biosimilar	18/09/23
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe	03/05/23
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23
EirGenix Inc. announced a financing transaction	10/03/23
EirGenix Inc. Announces Executive Changes	10/01/23
Eirgenix Inc. Announces Establishment of Corporate Governance Committee	28/12/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas EirGenix Inc.

Acciones

6589

TW0006589005

Otros idiomas

Filtros